Fox Run Management L.L.C. Invests $789,000 in Johnson & Johnson (NYSE:JNJ)

Fox Run Management L.L.C. acquired a new position in shares of Johnson & Johnson (NYSE:JNJFree Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,064 shares of the company’s stock, valued at approximately $789,000.

Other large investors also recently modified their holdings of the company. Hibernia Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson during the third quarter worth $27,000. FNY Investment Advisers LLC acquired a new stake in Johnson & Johnson in the third quarter worth $37,000. Tower View Wealth Management LLC grew its holdings in Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares during the period. Creative Capital Management Investments LLC grew its holdings in Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after purchasing an additional 86 shares during the period. Finally, VitalStone Financial LLC acquired a new stake in Johnson & Johnson in the second quarter worth $48,000. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have weighed in on JNJ shares. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, November 17th. UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Wells Fargo & Company lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $170.00 to $163.00 in a research note on Wednesday, December 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Tuesday. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $176.14.

Read Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $157.98 on Thursday. The firm has a market cap of $380.30 billion, a price-to-earnings ratio of 11.44, a P/E/G ratio of 2.62 and a beta of 0.53. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The firm’s 50-day simple moving average is $158.20 and its two-hundred day simple moving average is $159.04.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. The firm had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The company’s revenue was down 9.7% on a year-over-year basis. During the same quarter last year, the company earned $2.35 earnings per share. As a group, equities analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be paid a $1.19 dividend. The ex-dividend date is Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.01%. Johnson & Johnson’s dividend payout ratio is presently 34.47%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.